Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. It is not yet known whether combination chemotherapy is more effective with or without
rituximab in treating patients with non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying four different combination chemotherapy
regimens and rituximab to see how well they work compared to four different combination
chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.